We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · June 08, 2022

MTAP Deficiency Creates an Exploitable Target for Antifolate Therapy in 9p21-Loss Cancers

Nature Communications


Additional Info

Nature Communications
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
Nat Commun 2022 Apr 04;13(1)1797, O Alhalabi, J Chen, Y Zhang, Y Lu, Q Wang, S Ramachandran, RS Tidwell, G Han, X Yan, J Meng, R Wang, AG Hoang, WL Wang, J Song, L Lopez, A Andreev-Drakhlin, A Siefker-Radtke, X Zhang, WF Benedict, AY Shah, J Wang, P Msaouel, M Zhang, CC Guo, B Czerniak, C Behrens, L Soto, V Papadimitrakopoulou, J Lewis, W Rinsurongkawong, V Rinsurongkawong, J Lee, J Roth, S Swisher, I Wistuba, J Heymach, J Wang, MT Campbell, E Efstathiou, M Titus, CJ Logothetis, TH Ho, J Zhang, L Wang, J Gao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading